# IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults

> **NCT03092791** · PHASE1,PHASE2 · TERMINATED · sponsor: **Takeda** · enrollment: 340 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
- **BIOLOGICAL:** Reference IPV
- **BIOLOGICAL:** sIPV Placebo

## Key facts

- **NCT ID:** NCT03092791
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-07
- **Primary completion:** 2018-04-03
- **Final completion:** 2018-10-18
- **Target enrollment:** 340 (ACTUAL)
- **Why stopped:** Planned immunogenicity outcomes not reached
- **Last updated:** 2020-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03092791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03092791, "IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03092791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*